Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 153.14 -0.01 (-0.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 9 Next > So Much For Expecting The Fed To Stick The Landing Today 12:44 EDT Now is not the time to be fully invested. Via Talk Markets Topics Economy Exposures Interest Rates Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review August 02, 2024 Apple and Meta had strong results, while AI spending remains robust. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences August 01, 2024 Via Benzinga NASDAQ:NBIX, a strong growth stock, setting up for a breakout. July 26, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. Via Chartmill NASDAQ:NBIX, a growth stock which is not overvalued. July 26, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. Via Chartmill Should Quality Investors Include NASDAQ:NBIX in Their Portfolio? July 25, 2024 Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. Via Chartmill Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences July 10, 2024 Via Benzinga Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. July 05, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. Via Chartmill NASDAQ:NBIX is not too expensive for the growth it is showing. July 05, 2024 Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors. July 04, 2024 Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock. Via Chartmill Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued. June 20, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. Via Chartmill 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. Via InvestorPlace Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? June 14, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill Key Takeaways From Neurocrine Biosciences Analyst Ratings May 28, 2024 Via Benzinga Exploring NASDAQ:NBIX's quality characteristics. May 27, 2024 Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. May 24, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. Via Chartmill Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans June 14, 2024 Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. Via Investor's Business Daily Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. June 13, 2024 Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. Via Chartmill In the world of growth stocks, NASDAQ:NBIX shines as a value proposition. May 23, 2024 Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam May 04, 2024 The market rally appears to be picking up steam. Via Investor's Business Daily A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation May 03, 2024 Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. Via Investor's Business Daily Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. May 03, 2024 Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill NASDAQ:NBIX, a strong growth stock, setting up for a breakout. May 02, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences May 01, 2024 Via Benzinga Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review May 03, 2024 The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. Via Investor's Business Daily Topics Economy Exposures Interest Rates Despite its growth, NASDAQ:NBIX remains within the realm of affordability. May 02, 2024 Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. Via Chartmill PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 May 01, 2024 PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. Via Investor's Business Daily NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win May 01, 2024 The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia. Via Investor's Business Daily Sarepta Therapeutics Stock Shows Improved Technical Strength April 29, 2024 The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.